On May 26, SillaJen announced that early clinical research results for its anticancer drug candidate BAL0891, currently under development, were released at the American Society of Clinical Oncology (ASCO). ASCO, the world's largest oncology society, will hold its annual meeting (ASCO2026) from May 29 to June 2 (local time) in Chicago, Illinois, USA.

SillaJen Presents BAL0891 Clinical Research Data at ASCO View original image

According to the abstract released on the official website, the study aimed to assess the safety of BAL0891 and gradually escalate the dosage. Among 23 patients administered with a very low dose (5mg), sequential dose escalation was successfully achieved without any notable adverse effects. In a group of eight patients who received a higher dose (120mg or more), the efficacy of BAL0891 was observed. There was one case of complete response (CR), one case of partial response (PR), and three cases of stable disease (SD). Additionally, in a clinical group of eight patients who received BAL0891 in combination with paclitaxel, three PRs and four SDs were observed, resulting in a high disease control rate (DCR) of 87.5%.


This is especially meaningful given that most of the patients in this clinical trial were severe cases who had previously undergone two or more metastatic cancer treatments.


Furthermore, according to the information disclosed in the abstract, the maximum tolerated dose (MTD) in monotherapy was identified as 240mg, and the recommended phase 2 dose (RP2D) was determined to be 160mg. This results in a safety margin of 80mg between the two doses, which is expected to provide a significant advantage in future development.



A SillaJen representative stated, "Although these are still early data, the significance lies in having successfully determined both the safety and the recommended phase 2 dose (RP2D). Both domestic and international researchers will continue to do their utmost to validate the therapeutic value of BAL0891."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing